🕵️ Atrium Therapeutics, Inc. ($RNA)
SEC insider & ownership activity, last 12 months · CIK 2093101 · every row links its SEC filing
Insiders were quiet over the last 12 months – no open-market buys or sells. No red-flag 8-Ks in the window.
Insider flow
0 buyers, $0 (0 lots) · 0 sellers, $0 (0 lots)
No open-market insider transactions in the last 12 months.
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 8.8% | 13G | Aug 14, 2026 | filing ↗ | |
| John Petry | 8.8% | 13G | Aug 14, 2026 | filing ↗ | |
| T. ROWE Price Associates, Inc. | 8.6% | 13G | Aug 14, 2026 | filing ↗ | |
| BlackRock, Inc. | 6.6% | 13G | Jul 27, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Earnings (2.02) | Aug 13, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 13, 2026 | filing ↗ |
| Other events (8.01) | Jul 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 14, 2026 | filing ↗ |
| Earnings (2.02) | May 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 14, 2026 | filing ↗ |
| Material agreement (1.01) | Feb 26, 2026 | filing ↗ |
| Change of control (5.01) | Feb 26, 2026 | filing ↗ |
| Officer/director changes (5.02) | Feb 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 26, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 26, 2026 | filing ↗ |